The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting resilience across the healthcare and real estate sectors, Baxter International and UDR reported strong second-quarter 2026 financial results that surpassed analyst estimates. Baxter reported adjusted earnings per share (EPS) of $0.56, significantly beating the estimated $0.36, driven by robust demand in its drug compounding and advanced surgery segments. Consequently, the company raised its 2026 sales growth forecast to a range of 3%-4% and increased its adjusted EPS guidance.
Separately, the real estate investment trust UDR reported adjusted funds from operations (FFOA) of $0.64 per share, exceeding market expectations. However, Goldman Sachs adopted a cautious stance by lowering UDR's price target to $38, citing market headwinds such as slow rent recovery and oversupply. Per market data, Goldman Sachs (GS) shares closed at $1024.86 on July 30, 2026, while peers JPM and MS stood at $1024.86 and $210.13 respectively as of the same date.
Investors are now watching for the sustainability of this growth amid current market volatility, with GS priced at $1024.86 (close July 30, 2026) after a daily range between $998.51 and $1029.79. Looking ahead, traders are assessing the impact of recent monetary policy shifts, including the Fed Interest Rate Decision on July 29, to gauge the future trajectory for the real estate and healthcare sectors.